Cholesterol as a Potential Target for Castration-Resistant Prostate Cancer (Q37777663)

23 August 2017

1 reference

title

Cholesterol as a potential target for castration-resistant prostate cancer (English)

1 reference

23 August 2017

Cholesterol as a Potential Target for Castration-Resistant Prostate Cancer (English)

1 reference

https://api.crossref.org/works/10.1007/S11095-010-0210-Y

16 June 2024

1 reference

3

Kishor M Wasan

1 reference

23 August 2017

Alexis L. Twiddy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20683646

16 June 2024

Carlos G. Leon

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20683646

16 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20683646

16 June 2024

publication date

4 August 2010

1 reference

full work available at URL

23 August 2017

http://link.springer.com/content/pdf/10.1007/s11095-010-0210-y.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S11095-010-0210-Y

http://link.springer.com/article/10.1007/s11095-010-0210-y/fulltext.html

16 June 2024

1 reference

https://api.crossref.org/works/10.1007/S11095-010-0210-Y

http://link.springer.com/content/pdf/10.1007/s11095-010-0210-y

16 June 2024

1 reference

https://api.crossref.org/works/10.1007/S11095-010-0210-Y

16 June 2024

published in

Pharmaceutical Research

1 reference

23 August 2017

volume

28

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

423-437

1 reference

23 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

21 January 2018

Cancer in Canada in 2008

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Androgen, estrogen, and progesterone receptors in normal and aging prostates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Enzymes of Androgen Formation and Degradation in the Human Prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Mitochondrial function in Leydig cell steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Regulation of the steroidogenic acute regulatory protein gene expression: present and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Molecular biology of steroid hormone synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Mechanisms of the development of androgen independence in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Effects of low testosterone levels and of adrenal androgens on growth of prostate tumor models in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

The androgen axis in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Current Status of Bilateral Adrenalectomy or Advanced Prostatic Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Cellular cholesterol trafficking and compartmentalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

The role of cholesterol in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Cholesterol and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Insulin resistance and prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Trends and patterns of prostate cancer: what do they suggest?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Beta-carotene and animal fats and their relationship to prostate cancer risk. A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Prospective study of serum cholesterol and site-specific cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Serum cholesterol and the incidence of cancer in a large cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Serum cholesterol levels in patients with cancer. Relationship with nutritional status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Androgen deficiency and atherosclerosis: The lipid link

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Estrogen treatment of prostate cancer increases triglycerides in lipoproteins as demonstrated by HPLC and immunoseparation techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Scavenger receptor class BI and selective cholesteryl ester uptake: partners in the regulation of steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Cholesterol sensing, trafficking, and esterification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Androgens, lipogenesis and prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Cholesterol homeostasis in two commonly used human prostate cancer cell-lines, LNCaP and PC-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Do the cholesterol-lowering properties of statins affect cancer risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Acyl-coenzyme A:cholesterol acyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: impact on hepatic cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

SR-BI-mediated HDL cholesteryl ester delivery in the adrenal gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Hormone-sensitive lipase is required for high-density lipoprotein cholesteryl ester-supported adrenal steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Lipid dependence of ABC transporter localization and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Signaling by the high-affinity HDL receptor scavenger receptor B type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

The selective pathway and a high-density lipoprotein receptor (SR-BI) in ovarian granulosa cells of the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Measurement of cholesterol bidirectional flux between cells and lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Control of cholesterol turnover in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

SR-BI and HDL cholesteryl ester metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Localization and regulation of SR-BI in membrane rafts of HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Estrogen regulation of the scavenger receptor class B gene: Anti-atherogenic or steroidogenic, is there a priority?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Impact of gene variants on sex-specific regulation of human Scavenger receptor class B type 1 (SR-BI) expression in liver and association with lipid levels in a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Scavenger receptor class B type I-mediated uptake of serum cholesterol is essential for optimal adrenal glucocorticoid production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Breast and prostate cancer: more similar than different.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Consequences of over-expression of rat Scavenger Receptor, SR-BI, in an adrenal cell model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

The evolving biology and treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Expression and function of androgen receptor coactivators in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Statins and prostate cancer prevention: where we are now, and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Passive and active drug targeting: drug delivery to tumors as an example

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Statin induces apoptosis and cell growth arrest in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

siRNA delivery systems for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

RNAi therapeutics: a potential new class of pharmaceutical drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Aptamer-targeted cell-specific RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Aptamer mediated siRNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Inhibition of lung carcinoma cell growth by high density lipoprotein-associated alpha-tocopheryl-succinate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Atorvastatin and Celecoxib Inhibit Prostate PC-3 Tumors in Immunodeficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-010-0210-Y

The Risk of Cancer in Users of Statins

21 January 2018

1 reference

12 December 2020

Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up

1 reference

12 December 2020

Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice.

1 reference

12 December 2020

Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model

1 reference

12 December 2020

High density lipoprotein and low density lipoprotein utilization by human granulosa cells for progesterone synthesis in serum-free culture: respective contributions of free and esterified cholesterol

1 reference

12 December 2020

1 reference

12 December 2020

Prolonged stimulation of the adrenals by corticotropin suppresses hepatic low-density lipoprotein and high-density lipoprotein receptors and increases plasma cholesterol

1 reference

12 December 2020

Effects of dietary fatty acids on DU145 human prostate cancer cell growth in athymic nude mice

1 reference

12 December 2020

High- and low-density lipoproteins stimulate progesterone production in cultured human granulosa cells

1 reference

12 December 2020

Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Cholesterol, lipoproteins, and coronary heart disease in women

1 reference

12 December 2020

Management of dyslipidemia

1 reference

12 December 2020

Hormonal therapy for advanced prostatic carcinoma

1 reference

12 December 2020

Prostate-specific antigen in prostate cancer.

1 reference

12 December 2020

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

1 reference

12 December 2020

Prostate cancer epidemiology

1 reference

12 December 2020

Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization

1 reference

12 December 2020

Remnant lipoproteins induced proliferation of human prostate cancer cell, PC-3 but not LNCaP, via low density lipoprotein receptor

1 reference

12 December 2020

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

1 reference

12 December 2020

The impact of HMG-CoA reductase therapy on serum PSA.

1 reference

12 December 2020

Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study

1 reference

12 December 2020

Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family

1 reference

12 December 2020

Relationship of androgen receptors to the growth and regression of the prostate

1 reference

12 December 2020

Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer.

1 reference

12 December 2020

Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

1 reference

12 December 2020

Establishment and characterization of a human prostatic carcinoma cell line (PC-3)

1 reference

12 December 2020

A human cell line from a pleural effusion derived from a breast carcinoma

1 reference

12 December 2020

Cholesterol and cholesterol-rich membranes in prostate cancer: an update

1 reference

12 December 2020

Diet and prostatic cancer: a case-control study in Hawaii

1 reference

12 December 2020

Cancer incidence by levels of cholesterol

1 reference

12 December 2020

Cultured human granulosa cells as a model for corpus luteum function: relative roles of gonadotrophin and low density lipoprotein studied under defined culture conditions

1 reference

12 December 2020

Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase

1 reference

12 December 2020

The LDL receptor is not necessary for acute adrenal steroidogenesis in mouse adrenocortical cells

1 reference

12 December 2020

Scavenger receptor class B, type I-mediated [3H]cholesterol efflux to high and low density lipoproteins is dependent on lipoprotein binding to the receptor

1 reference

12 December 2020

Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance

1 reference

12 December 2020

Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study

1 reference

12 December 2020

5

3

287

SL Goldenberg

1999

1 reference

https://api.crossref.org/works/10.1007/S11095-010-0210-Y

16 June 2024

Identifiers

1 reference

23 August 2017

1 reference